HCV Treatment
Sitges Meeting Discusses European Access to New Hepatitis C Drugs
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 17 June 2011 07:01
- Written by Sitges Meeting
Community activists, researchers, and regulatory and pharmaceutical representatives met this month in Sitges, Spain, to discuss early and expanded access to direct-acting antiviral agents for hepatitis C, especially for difficult-to-treat patients including those with HIV/HCV coinfection and cirrhosis. 
HCV Protease Inhibitor Danoprevir Promising in Early Trial
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 14 June 2011 07:54
- Written by Liz Highleyman
Experimental HCV protease inhibitor danoprevir (formerly RG7227 and ITMN-191) was safe and showed good antiviral activity at higher doses in a 14-day study of treatment-naive and previously treated genotype 1 chronic hepatitis C patients. 
Updated PegIntron Label Psychiatric Warning
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 14 June 2011 07:41
- Written by FDA
Package information for Intron-A conventional interferon and PegIntron pegylated interferon were updated with a warning that people with psychiatric and substance use disorders may experience worse symptoms. 
PSI-7977 Trial Adds New Regimens
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 14 June 2011 07:48
- Written by Pharmasset
The ELECTRON trial, testing the HCV polymerase inhibitor PSI-7977, has added new arms looking at regimens with shorter duration or no interferon for people with HCV genotypes 1, 2, and 3.
BI201335 Shows Potent Activity against HCV
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 07 June 2011 13:23
- Written by Liz Highleyman
HCV protease inhibitor BI201335 plus pegylated interferon/ribavirin was well-tolerated and demonstrated good activity in treatment-naive and -experienced genotype 1 chronic hepatitis C patients.
Web Design and Development by